Prosper: A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled, Efficacy And Safety Study Of Enzalutamide In Patients With Nonmetastatic Castration-resistant Prostate Cancer

Trial Profile

Prosper: A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled, Efficacy And Safety Study Of Enzalutamide In Patients With Nonmetastatic Castration-resistant Prostate Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs Enzalutamide (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms PROSPER
  • Sponsors Medivation; Pfizer
  • Most Recent Events

    • 14 Sep 2017 According to a Pfizer media release, based on the result of this study, company intend to discuss the data with global health authorities to potentially support expanding the label for XTANDI to cover all patients with Castration-Resistant Prostate Cancer.
    • 14 Sep 2017 Primary endpoint has been met. (Metastasis free survival (MFS))
    • 21 Aug 2017 Planned End Date changed from 1 Dec 2020 to 31 May 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top